Breaking News Instant updates and real-time market news.

EW

Edwards Lifesciences

$225.67

3.75 (1.69%)

, TSLA

Tesla

$255.10

-0.52 (-0.20%)

13:59
10/23/19
10/23
13:59
10/23/19
13:59

Notable companies reporting after market close

Notable companies reporting after the market close, with earnings consensus, include Microsoft (MSFT), consensus $1.24... PayPal (PYPL), consensus 52c... Tesla (TSLA), consensus (42c)... Edwards Lifesciences (EW), consensus $1.22... Las Vegas Sands (LVS), consensus 75c... ServiceNow (NOW), consensus 88c... Ford Motor (F), consensus 26c... Lam Research (LRCX), consensus $3.01... eBay (EBAY), consensus 64c... O'Reilly Automotive (ORLY), consensus $4.79... Xilinx (XLNX), consensus 89c... Equifax (EFX), consensus $1.44... Align Technology (ALGN), consensus $1.14... BioMarin Pharmaceutical (BMRN), consensus 6c... Fortune Brands (FBHS), consensus 98c... SLM Corp (SLM), consensus 25c... Spirit Airlines (SAVE), consensus $1.23.

EW

Edwards Lifesciences

$225.67

3.75 (1.69%)

TSLA

Tesla

$255.10

-0.52 (-0.20%)

PYPL

PayPal

$95.99

-1.41 (-1.45%)

MSFT

Microsoft

$136.25

-0.14 (-0.10%)

LVS

Las Vegas Sands

$59.16

0.58 (0.99%)

NOW

ServiceNow

$218.68

-9.58 (-4.20%)

F

Ford

$9.04

-0.025 (-0.28%)

LRCX

Lam Research

$233.15

-1.76 (-0.75%)

EBAY

eBay

$39.03

0.06 (0.15%)

ORLY

O'Reilly Automotive

$400.41

-0.16 (-0.04%)

XLNX

Xilinx

$95.26

-0.75 (-0.78%)

EFX

Equifax

$139.11

-0.15 (-0.11%)

ALGN

Align Technology

$217.63

4 (1.87%)

BMRN

BioMarin

$69.77

2.04 (3.01%)

FBHS

Fortune Brands

$58.73

0.22 (0.38%)

SLM

Sallie Mae

$9.10

0.04 (0.44%)

SAVE

Spirit Airlines

$37.74

0.49 (1.32%)

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 23

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 24

    Oct

  • 26

    Oct

  • 27

    Oct

  • 28

    Oct

  • 29

    Oct

  • 29

    Oct

  • 29

    Oct

  • 30

    Oct

  • 30

    Oct

  • 31

    Oct

  • 04

    Nov

  • 05

    Nov

  • 06

    Nov

  • 13

    Nov

  • 14

    Nov

  • 19

    Nov

  • 20

    Nov

  • 21

    Nov

  • 21

    Nov

  • 07

    Dec

  • 09

    Dec

  • 12

    Dec

EW Edwards Lifesciences
$225.67

3.75 (1.69%)

10/22/19
RBCM
10/22/19
NO CHANGE
Target $250
RBCM
Outperform
Edwards Lifesciences price target raised to $250 from $217 at RBC Capital
RBC Capital analyst Brandon Henry raised his price target on Edwards Lifesciences to $250 and kept his Outperform rating going into its Q3 results. The analyst notes that the consensus forecast for U.S. transcatheter aortic valve replacement, or TAVR, is high with estimated growth rate in high teens, though the buy-side is estimating that rate to be over 20%. Henry adds that the company stands to benefit from the August FDA approval of SAPIEN 3 for low-risk patients and from its "landmark" Partner 3 results.
07/24/19
RAJA
07/24/19
NO CHANGE
Target $232
RAJA
Outperform
Edwards Lifesciences price target raised to $232 from $200 at Raymond James
Raymond James analyst Jayson Bedford raised his price target for Edwards Lifesciences to $232 from $200 on increased confidence given a sharp acceleration in TAVR growth and an earlier than expected approval for Low Risk. The analyst reiterates an Outperform rating on the shares.
10/14/19
FBCO
10/14/19
NO CHANGE
Target $261
FBCO
Outperform
Edwards Lifesciences price target raised to $261 from $226 at Credit Suisse
Credit Suisse analyst Matt Miksic raised his price target for Edwards Lifesciences to $261 from $226 as rising confidence in U.S. TAVR market drives stock and expectations higher. The analyst notes that the stock has "significantly" outperformed his universe over the past few months and year to date, driven by superiority of Low-Risk TAVR clinical trial results in March, and "very strong" performance of the company's U.S. TAVR business in Q2. Feedback on this market from clinicians remains positive, and Street estimates have creeped higher in recent weeks as a result, he adds. Miksic reiterates an Outperform rating on the shares.
09/23/19
PIPR
09/23/19
INITIATION
Target $240
PIPR
Overweight
Edwards Lifesciences initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Adam Maeder started Edwards Lifesciences with an Overweight rating and $240 price target. While the company trades at "multiple turns" above its large-cap peers, the stock can continue to work at current levels, Maeder tells investors in a research note. The analyst believes there is still upside to the "already high" Street expectations in the second half of 2019 and 2020. U.S. low-risk approval should give the broader transcatheter aortic valve replacement market "a shot in the arm," says Maeder.
TSLA Tesla
$255.10

-0.52 (-0.20%)

10/18/19
WEDB
10/18/19
NO CHANGE
Target $220
WEDB
Neutral
Tesla's deliviery guidance 'ambitious,' 'difficult task,' says Wedbush
Wedbush analyst Daniel Ives reiterated a Neutral rating and $220 price target on Tesla, saying he continues to be cautious on the story ahead of the company's Q3 results on October 23. In a research note to investors, Ives says that while the company did hit the target set back in July to sequentially increase the amount of vehicles delivered, he notes that it was only by about 1,700 units and that in order to hit its ambitious unit guidance of 360,000-400,000, the company will have to deliver about 105,000 vehicles in Q4, which he continues to view as a "difficult" task. Ives expects China will be a major focus of the company's conference call, as it remains a hot topic among the Street.
10/18/19
RBCM
10/18/19
NO CHANGE
Target $190
RBCM
Underperform
Tesla Q3 expectations elevated, says RBC Capital
RBC Capital analyst Joseph Spak is keeping his Underperform rating and $190 price target on Tesla ahead of its Q3 results. The analyst contends that rumors of the start of Model Y production before the previously expected late-2020 period suggests that the demand for Model 3's in the U.S. may be waning. Spak estimates that Model Y U.S. opportunity could be as high as 200K units, but warns that Model 3 may see cannibalization of 20% in the U.S. and 15% internationally from Model Y launch.
10/22/19
JMPS
10/22/19
NO CHANGE
JMPS
Market Perform
Tesla to post flat revenue in Q3, says JMP Securities
JMP Securities analyst Joseph Osha is keeping his Market Perform rating on Tesla ahead of its Q3 results tomorrow. The analyst notes that the company's reported production figures suggest that its revenue should be "almost exactly flat" sequentially and also show no major shift in product mix. Osha adds that the company has made some progress in bringing production more in line with shipments, which should result in greater cost absorption and a moderate increase in gross margin, but overall expects the investor focus to fall on Tesla's Q4 guidance.
10/22/19
ROTH
10/22/19
NO CHANGE
Target $224
ROTH
Neutral
Questions on competition remain for Tesla, says Roth Capital
Heading into Q3 earnings, Roth Capital analyst Craig Irwin says that shares of Tesla are trading at the top of the recent trading range on an optimistic assessment of competitive pressures. The Q3 deliveries number was a miss, so he thinks investors need to "carefully analyze pressures causing weakness." The China facility is a knock down, so Tesla can provide "nearly any capacity number it chooses," and deliveries in China are now the most likely enabler of Tesla meeting 2019 guidance. Irwin has a Neutral rating and $224 price target on the shares.
PYPL PayPal
$95.99

-1.41 (-1.45%)

10/09/19
BTIG
10/09/19
NO CHANGE
Target $130
BTIG
Buy
BTIG lowers Q3 EPS view for PayPal after projected investment losses
BTIG analyst Mark Palmer lowers his Q3 EPS view on Paypal to 54c from 69c after the company disclosed an expected 15c impact in the quarter from unrealized losses in its strategic investment portfolio. The analyst is keeping his Buy rating and $130 price target on the stock however, citing the company's "differentiated assets" and "trusted brand" sustaining its leading position in digital payments.
09/24/19
UBSW
09/24/19
NO CHANGE
Target $120
UBSW
Neutral
PayPal leads among P2P providers, app share remains stable, says UBS
UBS analyst Eric Wasserstrom is keeping his Neutral rating and $120 price target on PayPal as part of his broader research note into U.S. Payment Networks. The analyst states that his most recent UBS Evidence Lab Mobile Banking App Download data suggests that mobile payment apps continue to gain market share relative to the traditional banking apps, and within that category, remittance apps continue to lose share vs. P2P apps like Venmo. Wasserstrom adds that PayPal - while challenged by newer entrants like Square Cash - is still maintaining its leading position in P2P. The analyst maintains however that Venmo's contribution to PayPal's revenue and earnings is already reflected in the stock's premium multiple relative to its historical levels.
10/01/19
ADAM
10/01/19
NO CHANGE
Target $118
ADAM
Buy
PayPal payment processor deal beats card networks to China, says Canaccord
Canaccord analyst Joseph Vafi said Paypal's (PYPL) disclosure of its controlling stake in Chinese payment player GoPay has material strategic implications longer term. The analyst notes the deal allowed PayPal to beat both Visa (V) and Mastercard (MA) into the Chinese market and could be a conduit to drive meaningful cross-border payments volume allowing it to continue to sustain mid 20% payment volume for the next several years. Vafi reiterated his Buy rating and $118 price target on PayPal shares.
10/10/19
NOMU
10/10/19
NO CHANGE
Target $139
NOMU
Buy
PayPal likely to sign more Chinese partnerships, says Nomura Instinet
On the heels of PayPal's recent GoPay acquisition, more partnerships with Chinese mobile payments players may be in the works, Nomura Instinet analyst Bill Carcache tells investors in a research note. The analyst believes the GoPay deal has raised the possibility of more "mutually beneficial partnerships" between PayPal and key players inside China's payments ecosystem. He keeps a Buy rating on the shares with a $139 price target.
MSFT Microsoft
$136.25

-0.14 (-0.10%)

10/21/19
JEFF
10/21/19
NO CHANGE
JEFF
High growth software valuations to contract further, says Jefferies
High growth software valuations are now trading above terminal M&A multiples, suggesting we still have more room for multiple contraction, Jefferies analyst Brent Thill tells investors in a research note. As such, the analyst expects the short term correction will continue "given multiples remain elevated even with last week's correction." Thill favors platform names with attractive growth and reasonable valuations like Microsoft (MSFT), Salesforce (CRM) and Intuit (INTU). He also favors names like SailPoint (SAIL), Zuora (ZUO), and Varonis (VRNS). The analyst believes these names have the potential for revenue reacceleration over the next year.
10/16/19
WBLR
10/16/19
NO CHANGE
WBLR
Outperform
Slack overhang from Microsoft competition should dissipate, says William Blair
After hosting investor meetings with Slack Technologies (WORK) management, William Blair analyst Bhavan Suri has "increased confidence in the story." While there was plenty of focus on the competitive environment with Microsoft (MSFT) and its Teams offering, much of the conversation also focused on the company's internal growth initiatives, its ability to continue winning large enterprise customers, its customer acquisition strategy, and the path to free cash flow breakeven, Suri tells investors in a research note. Management views Slack as having a different value proposition than Teams, says the analyst. Although the Microsoft overhang may remain with the stock for the next couple of quarters, it should dissipate over time as the company continues to execute and showcases its ability to win customers that are also using Office 365 for other functions, Suri contends. He believes Slack is well positioned long-term to continue "winning in the space" and sees a "long growth runway" for the company. The analyst keeps an Outperform rating on the shares.
10/18/19
RBCM
10/18/19
INITIATION
Target $160
RBCM
Outperform
Microsoft assumed with an Outperform at RBC Capital
RBC Capital analyst Alex Zukin assumed coverage of Microsoft with an Outperform rating with a price target of $160, up from $153. The analyst believes that the company is "best positioned to outperform" over the next several years as it becomes a "strategic partner" to digital transformations among large enterprises, with mission-critical capabilities of its key portfolio assets - Azure and Office365. Zukin adds that Microsoft's Q1 revenue and earnings should see a "typical" period of outperformance, as he raises his FY20 EPS view by 6c to $5.21 and sees expectations of a 55% Azure growth next year as "reasonable".
10/18/19
CLVD
10/18/19
NO CHANGE
CLVD
Buy
Microsoft partners look to have finished ahead of plan, says Cleveland Research
Cleveland Research analyst Ari Terjanian said his checks suggests Microsoft partners finished ahead of plan in the company's fiscal first quarter and they are modeling Productivity and Business Processes and Intelligent Cloud results that are ahead of consensus. Feedback on the More Personal Computing segment is more mixed at partners, with strength in Win10 migrations and M365 upgrades seen being offset by some headwinds in PC and gaming, added Terjanian, who reiterated his Buy rating on Microsoft shares.
LVS Las Vegas Sands
$59.16

0.58 (0.99%)

09/09/19
DBAB
09/09/19
UPGRADE
Target $70
DBAB
Buy
Deutsche upgrades Las Vegas Sands to Buy amid bearish Macau sentiment
Deutsche Bank analyst Carlo Santarelli last night upgraded Las Vegas Sands to Buy from Hold with a price target of $70. Bearish Macau sentiment has created an opportunistic entry point for medium to longer term investors, Santarelli tells investors in a research note. The analyst believes the shares at current levels do not reflect Las Vegas Sands' "fortified" balance sheet and capital return story. Santarelli attributes Macau's "choppy" trends to geopolitical headwinds and he expects positive Macau gross gaming revenue comparisons in the near term.
09/09/19
09/09/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Las Vegas Sands (LVS) upgraded to Buy from Hold at Deutsche Bank with analyst Carlo Santarelli saying Bearish Macau sentiment has created an opportunistic entry point for medium to longer term investors. 2. Genesco (GCO) upgraded to Buy from Hold at Pivotal Research with analyst Mitch Kummetz citing the company's Q2 beat and guidance increase. 3. Entergy (ETR) upgraded to Overweight from Neutral at JPMorgan with analyst Christopher Tenure saying unlike some of its large premium valuation peers, Entergy has potential for both high rate base growth and improving earned returns on equity. 4. SAIC (SAIC) upgraded to Outperform from Market Perform at Cowen with analyst Cai Von Rumohr saying the "sharp selloff" in shares has resulted in favorable risk/reward and raised its price target to $102.00. 5. Chipotle (CMG) upgraded to Outperform from Neutral at Wedbush with analyst Nick Setyan saying as the industry transitions towards a larger mix of digital transactions, the analyst believes Chipotle is in a leading position to establish a digital moat. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/17/19
MSCO
09/17/19
NO CHANGE
MSCO
Las Vegas Sands, MGM, Wynn targets cut at Morgan Stanley on Macau estimate cuts
Morgan Stanley analysts Thomas Allen and Praveen Choudhary lowered their expectations for Macau, stating they now expects gross gaming revenue to decline 3% in 2019 and grow 3% in 2020. The analysts previously forecast a 1% decline in GGR for 2019 and an 8% increase in 2020. Allen lowered his price target on Las Vegas Sands (LVS) to $66 from $68, cut his target on MGM Resorts (MGM) to $31 from $32 and reduced his Wynn Resorts (WYNN) target to $115 from $129, explaining that the Wynn cut is most pronounced since it is most exposed to Macau and to the weak high-end there. He maintains an Overweight rating on Las Vegas Sands, which he views as the most defensive and with potential Japan upside. Allen has Equal Weight ratings on MGM and Wynn shares.
09/24/19
GSCO
09/24/19
UPGRADE
Target $155
GSCO
Buy
Wynn Resorts upgraded to Buy from Neutral at Goldman Sachs
Goldman Sachs analyst Stephen Grambling upgraded Wynn Resorts (WYNN) to Buy from Neutral and raised his price target for the shares to $155 from $140. The company's free cash flow is set to inflect as major capital projects are completed, Grambling tells investors in a research note. Further, Wynn's projects ramping in Boston and Las Vegas should provide domestic growth while leading indicators and recent data points suggest Macau gaming revenue is stabilizing with potential for upside, adds the analyst. Grambling raised price targets across the gaming space for those companies exposed to Macau. The space is set for outperformance, says the analyst, who now has Buy ratings on Las Vegas Sands (LVS), Red Rock Resorts (RRR), VICI Properties (VICI) and Wynn Resorts.
NOW ServiceNow
$218.68

-9.58 (-4.20%)

10/23/19
10/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Walgreens Boots Alliance (WBA) downgraded to Neutral from Overweight at JPMorgan with analyst Lisa Gill saying she based on her relative rating methodology, seeing better opportunities for upside in other companies within her coverage universe at the current time. 2. Cheniere Energy Partners (CQP) downgraded to Underperform at Raymond James with analyst Justin Jenkins saying that while his firm's North American energy macro outlook remains favorable for exporters from a supply-push perspective, he sees this as priced into Cheniere shares. 3. Resideo (REZI) downgraded to Perform from Outperform at Oppenheimer with analyst Ian Zaffino saying the company, once again, revised guidance negatively. 4. ServiceNow (NOW) downgraded to Neutral from Buy at Mizuho with analyst Gregg Moskowitz saying the company last night surprisingly announced the impending departure of CEO John Donahoe, who is going to head Nike (NKE), and lowered its full year guidance due to currency. 5. Kohl's (KSS) downgraded to In Line from Outperform at Evercore ISI. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/23/19
COWN
10/23/19
NO CHANGE
Target $315
COWN
Outperform
ServiceNow new CEO well-suited for next growth phase, says Cowen
Cowen analyst J. Derrick Wood noted ServiceNow (NOW) announced its CEO would be leaving to be CEO of Nike (NKE) and that ex-SAP (SAP) CEO Bill McDermott will take his place. The company also preannounced its Q3 results, beating estimates on billings growth and raising guidance on the high-end. The analyst noted the CEO change was a surprise but he believes McDermott's skill set should be well-suited for the company's next growth phase. Wood reiterated his Outperform rating and $315 price target on ServiceNow shares.
10/23/19
MACQ
10/23/19
NO CHANGE
Target $243
MACQ
Outperform
Macquarie a buyer of ServiceNow, says Bill McDermott a 'huge win'
Macquarie analyst Sarah Hindlian says that while she understands the uncertainty in ServiceNow shares around the departure of John Donahoe and the lack of a CFO appointment, she thinks the preliminary results "spoke volumes against the bear case." Further, the analyst sees incoming CEO Bill McDermott "as one of the best executives available in enterprise software." McDermott is a "huge win," contends Hindlian, who is a buyer of ServiceNow shares into today's conference call. She has a Buy rating on the stock with a $335 price target.
10/23/19
UBSW
10/23/19
NO CHANGE
Target $232
UBSW
Buy
ServiceNow stock price attractive following aftermarket decline, says UBS
UBS analyst Jennifer Lowe is keeping her Buy rating and $232 price target on ServiceNow (NOW) after the stock fell afterhours yesterday on the news that its CEO John Donahoe is leaving for a CEO post at Nike (NKE). The analyst notes that the company also pre-announced Q3 ahead of consensus while its FY19 outlook indicates no change to Q4 guidance. Lowe adds that although ServiceNow is faced with new CEO transition risk, the former SAP CEO Bill McDermott is also "seasoned", and the stock is "attractive" at a 29-times enterprise value to expected 2020 free cash flow.
F Ford
$9.04

-0.025 (-0.28%)

10/01/19
BUCK
10/01/19
NO CHANGE
Target $8
BUCK
Neutral
Ford price target lowered to $8 from $9 at Buckingham
Buckingham analyst Joseph Amaturo maintained a Neutral rating on Ford and lowered his price target to $8 from $9, citing a more cautious view of earnings per share and free cash flow for the second half of the year as well as heightened concerns for 2020. Amaturo tells investors in a research note that he is "pretty confident" Ford will fall meaningfully short of EPS and adjusted free cash flow expectations for the third quarter when it reports on October 23, and says he is becoming increasingly concerned about end market demand in many of the markets it participates in.
09/10/19
BOFA
09/10/19
NO CHANGE
Target $13
BOFA
Buy
Ford downgrade by Moody's may be sign of things to come, says BofA/Merrill
BofA Merrill Lynch analyst John Murphy said Ford's corporate borrowing costs will likely remain unchanged in the near-term despite Moody's downgrade of the company's senior unsecured rating to Ba1, or a junk status, since Ford faces no significant near-term debt maturities. While the financial implications seem "somewhat de minimis at present," Moody's move on Ford's credit rating could be a harbinger of future downgrades for the company and even for the broader automotive value chain, particularly for those undergoing turnaround efforts, said Murphy. While he does not disagree with many of the concerns raised by Moody's, Murphy thinks Ford's dividend will be maintained for the foreseeable future and views the near-term product cycle as robust. He also believes improved execution and communication may help Ford's multiple to recover despite the "somewhat disappointing" downgrade news, leading Murphy to keep a Buy rating on Ford shares.
09/27/19
MSCO
09/27/19
NO CHANGE
Target $12
MSCO
Overweight
Ford Q3 may lack 'punch,' but weakness would be opportunity, says Morgan Stanley
Morgan Stanley analyst Adam Jonas lowered his 2019 EPS forecast for Ford to $1.22 from $1.30 to account for his inclusion of estimated UAW contract ratification costs and also pointed to headwinds related to a challenging ramp-up of Explorer in Q3 and more losses from China imports in the second half. While he thinks Ford's Q3 report "may not pack a big punch," Jonas would see any related weakness in Ford shares as a buying opportunity as he is attracted to low expectations for Ford in the equity and debt markets. Jonas, who added that he likes the current setup for Ford "very much," reiterated his Overweight rating and $12 price target on the shares.
09/18/19
MSCO
09/18/19
NO CHANGE
Target $12
MSCO
Overweight
Ford details on EVs, cost savings to be catalysts, says Morgan Stanley
Morgan Stanley analyst Adam Jonas, in a note to investors titled "Ford Ready to Shock with BEV and Cost Savings?," said his conviction has increased, based on investor positioning and low expectations for Ford in the equity and debt market, that the company offering details around its battery electric vehicle plans and cost savings expectations can be catalysts for the stock. Ford has communicated $11B of restructuring charges, but hasn't made clear any annual savings targets so that consensus forecasts don't include them, Jonas said. He currently gives Ford credit for roughly $1B of restructuring savings and expects the company to outline its savings forecasts to the investment community within the next two quarters. Jonas, who also expect Ford's electrification strategy to shift from hybrids to battery electric over the next 24 months, reiterated his Overweight rating and $12 price target on Ford shares.
LRCX Lam Research
$233.15

-1.76 (-0.75%)

10/01/19
KEYB
10/01/19
NO CHANGE
KEYB
KeyBanc makes four Semiconductor rating changes after trip to Asia
KeyBanc analyst Weston Twigg made four rating changes in the Semiconductors space after his quarterly trip to Asia revealed overall demand trends, while still weak, "are not getting worse." The analyst was encouraged to find inventories are beginning to normalize and that expectations are for normal seasonality in Q4. As a result, he upgraded Analog Devices (ADI), Microchip (MCHP), and NXP Semiconductors (NXPI) to Overweight from Sector Weight. Conversely, the China insourcing trends at Huawei and other manufacturers are accelerating faster than Twigg had expected, which results in his downgrade of Xilinx (XLNX) to Sector Weight from Overweight. The analyst also recommends building long-term positions in semi-cap and memory stocks like KLA-Tencor (KLAC), Teradyne (TER), Micron Technology (MU), MKS Instruments (MKSI), Entegris (ENTG), Applied Materials (AMAT) and Lam Research (LRCX). Lastly, Twigg says that initial demand for Apple's (AAPL) new iPhone "appears to be slightly worse than expected."
09/18/19
NOMU
09/18/19
INITIATION
Target $216
NOMU
Neutral
Lam Research initiated with a Neutral at Nomura Instinet
Nomura Instinet analyst David Wong started Lam Research with a Neutral rating and $216 price target. The analyst sees near-term uncertainty in the semiconductor equipment business environment.
09/19/19
WELS
09/19/19
NO CHANGE
Target $235
WELS
Market Perform
Lam Research price target raised to $235 from $230 at Wells Fargo
Wells Fargo analyst Joe Quatrochi raised his price target for Lam Research to $235 from $200, while reiterating a Market Perform rating on the shares. The analyst thinks Lam's services business remains underappreciated, but notes that pushback from investors has consistently highlighted the lack of quarterly revenue disclosure with many focused on the mix of lumpier upgrades and refurbs versus long-term service contract penetration.
09/23/19
SBSH
09/23/19
UPGRADE
Target $68
SBSH
Buy
Advanced Energy upgraded to Buy from Neutral at Citi
Citi analyst Atif Malik upgraded Advanced Energy Industries (AEIS) to Buy from Neutral and raised his price target for the shares to $68 from $55. The analyst is moving to a "more offensive" Semiconductor Capital Equipment stance as he believes the memory market is showing signs of recovery and that 5G logic investments are accelerating, which adds confidence to his 2020/2021 wafer-fab equipment recovery thesis. Malik's top equipment picks remain Lam Research (LRCX) and Applied Materials (AMAT). He upgraded Advanced Energy to Buy and moved MKS Instruments (MKSI) to his favorite SMID cap pick. The analyst also likes KLA-Tencor (KLAC), Teradyne (TER) and Advanced Energy on their "5G appeal."
EBAY eBay
$39.03

0.06 (0.15%)

09/27/19
09/27/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Box (BOX) downgraded to Underweight from Neutral at JPMorgan with analyst Mark Murphy saying while the stock has run higher, competition is intensifying in Box's target markets. 2. Atara Biotherapeutics (ATRA) downgraded to Sell from Neutral at Goldman Sachs with analyst Salveen Richter saying he sees a lack of near-term catalysts for the stock and questions surrounding the company's clinical programs. 3. Carnival (CCL) downgraded to Sell from Hold at Berenberg and to Neutral from Buy at UBS. 4. eBay (EBAY) and Booking Holdings (BKNG) downgraded to Market Perform from Outperform at Wells Fargo. 5. Canopy Growth (CGC) downgraded to Neutral from Buy at BofA/Merrill with analyst Christopher Carey saying while he still sees Canopy as a long-term leader in the cannabis industry, he thinks Canada industry growth is set to pause in the second half and potentially flatten, which he thinks could also be the case with Canopy. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/21/19
DBAB
10/21/19
DOWNGRADE
Target $42
DBAB
Hold
eBay assumed with a Hold from Buy at Deutsche Bank
Deutsche Bank analyst Kunal Madhukar downgraded eBay to Hold from Buy after assuming coverage from prior analyst Lloyd Walmsley. The analyst lowered his price target for the shares to $42 from $46. eBay's gross merchandise volume growth has been "anemic" even as e-commerce has been growing double digits, Madhukar tells investors in a research note. The analyst expects the stock to be range-bound given the "challenging" competitive environment and the company's CEO transition. eBay is "searching for its identity and differentiation," says Madhukar, who sees more compelling opportunities elsewhere in the large-cap internet space.
09/26/19
WELS
09/26/19
DOWNGRADE
Target $45
WELS
Market Perform
eBay downgraded to Market Perform from Outperform at Wells Fargo
Wells Fargo analyst Brian Fitzgerald downgraded eBay to Market Perform from Outperform with an unchanged price target of $45. The company's slowing gross merchandise volume suggests stagnant or decreasing market share, Fitzgerald tells investors in a research note. Further, the analyst believes eBay's segment margins look lower than the activist investors are assuming in a breakup, which suggests to him "lower potential upside from the strategic review." Fitzgerald's sum-of-the-parts analysis lead him to believe that eBay shares are fairly valued. With that said, the company's 7.2% free cash flow and share buyback potentials limit downside risk on the stock, contends Fitzgerald.
10/08/19
BARD
10/08/19
NO CHANGE
Target $46
BARD
Outperform
eBay tracker indicates Q3 volumes in-line with expectations, says Baird
Baird analyst Colin Sebastian said his eBay sales volume tracker for September indicates volumes are in-line with expectations; suggesting volume declines moderated sequentially during the quarter. The analyst expects internet sales tax collection will remain a near-term headwind but noted management conservatism has likely embedded the negative impact of these tax changes through the balance of the year. Sebastian maintained his Outperform rating and $46 price target on eBay shares.
ORLY O'Reilly Automotive
$400.41

-0.16 (-0.04%)

10/07/19
RAJA
10/07/19
INITIATION
RAJA
Market Perform
O'Reilly Automotive resumed with a Market Perform at Raymond James
10/14/19
WELS
10/14/19
NO CHANGE
Target $440
WELS
Outperform
O'Reilly Automotive price target raised to $440 from $435 at Wells Fargo
Wells Fargo analyst Zachary Fadem raised his price target for O'Reilly Automotive to $440 from $435, while reiterating an Outperform rating on the shares. The analyst notes that the shares are 1%-plus since reporting Q2 results, and he sees a cleaner Q3 setup with likely comp acceleration, EBIT expansion potential and a potential increase in the fiscal year 2019 EPS outlook.
10/07/19
RAJA
10/07/19
INITIATION
RAJA
Market Perform
O'Reilly Automotive resumed with a Market Perform at Raymond James
Raymond James analyst Matthew McClintock resumed coverage of O'Reilly Automotive with a Market Perform rating. The analyst contends that even though the company is the "strongest operator" in the automotive aftermarket, the tightening competition and a relatively softer comp store sales trajectory warrant a neutral stance. McClintock adds that investors are unlikely to pay a higher valuation multiple, even though O'Reilly Auto has meaningful square footage growth opportunities in a number of untapped markets.
10/08/19
WOLF
10/08/19
UPGRADE
Target $436
WOLF
Outperform
O'Reilly Automotive upgraded to Outperform from Peer Perform at Wolfe Research
Wolfe Research analyst Chris Bottiglieri upgraded O'Reilly Automotive to Outperform from Peer Perform with a price target of $436, up from $371. The analyst said O'Reilly is the stock to own in an improving demand environment and notes May DIY headwinds are behind it, indicating some upside to comps relative to Q2's pace. Also, Bottiglieri expects price increases to continue, supporting comps, and views risk/reward as attractive.
XLNX Xilinx
$95.26

-0.75 (-0.78%)

10/23/19
BMOC
10/23/19
NO CHANGE
Target $100
BMOC
Market Perform
Xilinx price target lowered to $100 from $115 at BMO Capital
BMO Capital analyst Ambrish Srivastava lowered his price target on Xilinx to $100 and kept his Market Perform rating ahead of its earnings today. The analyst notes that the company may have to update its FY20 guidance calling for 15% revenue growth since fundamentals have "worsened considerably" since the management first made its forecasts at the analyst day, particularly in the communications segment.
10/14/19
10/14/19
UPGRADE

Fly Intel: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Nike (NKE) upgraded to Neutral from Underperform at BofA/Merrill with analyst Robert Ohmes saying that he expects the "accelerated democratization" of the brand to offset the broader future challenges around "significant" third-party retail store closures and global stagnation in "performance" footwear/apparel. 2. Western Digital (WDC) upgraded to Buy from Hold at Loop Capital with analyst Ananda Baruah citing his findings that flash memory average selling prices are set to increase starting in the September and December quarters while also sustaining those increases in 2020, along with expectations of strong hyperscale HDD demand next year. 3. Varian Medical (VAR) upgraded to Buy from Neutral at BTIG with analyst Sean Lavin saying Varian shares have pulled back in recent weeks and now trade in line with the comp group. 4. Xilinx (XLNX) upgraded to Buy from Neutral at Nomura Instinet with analyst David Wong saying many risks remain for U.S. semiconductor companies, including uncertainties related to U.S./China trade issues and U.S. action against Chinese companies such as Huawei. 5. HP Enterprise (HPE) upgraded to In Line from Underperform at Evercore ISI with analyst Amit Daryanani saying he is incrementally more positive on cash flow resiliency, the Cray acquisition, recent data points that indicate H3C is performing better than other OEMs in China, and valuation. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
10/22/19
CSND
10/22/19
UPGRADE
Target $115
CSND
Buy
Xilinx upgraded to Buy from Hold at Cascend Securities
Cascend Securities upgraded Xilinx to Buy from Hold with a $115 price target citing stronger hyperscale and AI deployment, better 5G, and a likely Industrial bottom from a macro standpoint.
10/13/19
NOMU
10/13/19
UPGRADE
Target $115
NOMU
Buy
Xilinx upgraded to Buy from Neutral at Nomura Instinet
Nomura Instinet analyst David Wong upgraded Xilinx (XLNX) to Buy from Neutral with an unchanged price target of $115. The stock closed Friday up $3.41 to $96.22. Many risks remain for U.S. semiconductor companies, including uncertainties related to U.S./China trade issues and U.S. action against Chinese companies such as Huawei, Wong tells investors in a research note. However, Xilinx's stock price and estimates have adjusted to reflect these risks, adds the analyst. He points out that the company is growing even with Huawei constraints. Xilinx has also gained meaningful share from Intel's (INTC) Altera in recent quarters, contends Wong.
EFX Equifax
$139.11

-0.15 (-0.11%)

03/15/19
EXAN
03/15/19
INITIATION
Target $106
EXAN
Neutral
Equifax initiated with a Neutral at Exane BNP Paribas
Exane BNP Paribas initiated Equifax with a Neutral and $106 price target.
07/22/19
STFL
07/22/19
NO CHANGE
Target $136
STFL
Hold
Equifax settlement cost in-line with expectations, says Stifel
Stifel analyst Shlomo Rosenbaum said he views the settlement agreement announced this morning by Equifax as relatively in line with his and the company's expectations and add that he expects incremental payments, if there are any, to be "very modest." The analyst, who said he thinks today's settlement is another key step in de-risking the story, keeps a Hold rating on Equifax shares but raised his price target on the stock to $136 from $115 to reflect higher valuations in the space and more certainty around the company.
07/30/19
ATLE
07/30/19
DOWNGRADE
ATLE
Neutral
TransUnion downgraded to Neutral from Overweight at Atlantic Equities
Atlantic Equities analyst Kunaal Malde downgraded TransUnion (TRU) to Neutral from Overweight saying he prefers shares of Equifax (EFX) at current levels.
07/26/19
RHCO
07/26/19
NO CHANGE
Target $155
RHCO
Buy
Equifax price target raised to $155 from $130 at SunTrust
SunTrust analyst Andrew Jeffrey raised his price target on Equifax to $155 and kept his Buy rating after its Q2 earnings beat. The analyst notes that while the soft Q3 outlook has weighed on the stock price after-hours, the weakness is creating an attractive entry point given the "apparent recovery in US Information Solutions sales momentum", "continued robust" Equifax Workforce Solutions segment performance, and a better margin outlook.
ALGN Align Technology
$217.63

4 (1.87%)

10/17/19
STFL
10/17/19
NO CHANGE
Target $290
STFL
Buy
Align Technology survey results support positive stance, says Stifel
Stifel analyst Jonathan Block said his recent survey work on Align Technology has been favorable and supports his positive stance, with providers citing "solid" Invisalign momentum at their practices, "healthy" 2020 case volume expectations, and little incremental progress from competing traditional clear aligner offerings. His checks also detected some acknowledgement of incremental Invisalign case volume resulting from Align's increased sales force investments, noted Block, who keeps a Buy rating and $290 price target on Align shares.
10/07/19
STFL
10/07/19
NO CHANGE
Target $290
STFL
Buy
Align Technology shares oversold at current levels, says Stifel
Stifel analyst Jonathan Block, who initiated coverage of SmileDirectClub (SDC) with a Buy rating and $19 price target this morning, said in a separate note to investors that he continues to view Align Technology (ALGN) as his preferred name in the clear aligner space. While challenges, such as foreign exchange headwinds and China's macro issues, remain, EMEA has been strong for the company and he "likes what he sees so far" within his proprietary U.S. due diligence, Block tells investors. He views Align shares as oversold at current levels and expects "worst case fears" around Align's share losses to SmileDirect to ease in coming quarters, Block noted. He keeps a Buy rating on Align shares with a $290 price target.
10/07/19
LEHM
10/07/19
NO CHANGE
Target $272
LEHM
Overweight
Barclays clear aligner survey positive for Align Technology
Barclays analyst Steve Valiquette views his clear aligner survey last week to gauge U.S. trends for Q3 as positive for Align Technology. Based on the survey, the analyst believes the U.S. volume outlook looks solid, and his Align Technology revenue growth assumptions of 21% in 2019 and 23% in 2020 are unchanged. Further, respondents indicated there was no notable Invisalign discounting program in Q3 beyond the normal volume-tier discounts, Valiquette tells investors in a research note. The analyst lowered his price target for Align Technology to $272 from $300 and keeps an Overweight rating on the shares.
10/23/19
NRCS
10/23/19
NO CHANGE
Target $299
NRCS
Buy
Northcoast analysis shows favorable utilization trends for Align's Invisalign
Northcoast analyst David Keiser says that despite a more competitive clear aligner market, his North American Invisalign doctor analysis suggests favorable utilization trends have continued. 13 additional Invisalign doctors in the analyst's sample size reached the four upper tiers of Align Technology's Invisalign Advantage Program, and he also saw a sequential increase of 85 Invisalign doctors in the Silver level of the Invisalign Advantage program. Keiser maintains a Q3 earnings per share estimate of $1.16 for Align Technology, which is 2c ahead of consensus. He reiterates a Buy rating on the shares with a $299 price target.
BMRN BioMarin
$69.77

2.04 (3.01%)

10/09/19
STFL
10/09/19
NO CHANGE
STFL
Hold
Bluebird Hem A collaboration not stock moving, but worth monitoring, says Stifel
Stifel analyst Benjamin Burnett said he does not expect news that Blubird Bio (BLUE) is entering the Hemophila A race via a collaboration with Novo Nordisk (NVO) to be stock moving, but he does think it is "certainly worth monitoring." Biomarin's (BMRN) gene therapy candidate Valrox sets "the bar for genetic medicines in heme A today," said Burnett, who noted that gene therapies from Spark (ONCE) and Pfizer (PFE) are also in the clinic. However, "there does appear to be room for efficacy improvement as none of the clinical data generated from genetic medicines to date is a clear home run," Burnett added in his note to investors. He keeps a Hold rating on Bluebird Bio shares.
09/13/19
PIPR
09/13/19
NO CHANGE
Target $120
PIPR
Overweight
Piper a buyer of BioMarin shares into next important data catalyst
Piper Jaffray analyst Christopher Raymond sees the vosoritide Phase 3 achondroplasia data, expected by early 2020, as the next important catalyst for shares of BioMarin Pharmaceutical. Assuming no surprises, vosoritide offers a "compelling" commercial premise, with "meaningful" upside to current expectations with little in the way of meaningful competition on the horizon, Raymond tells investors in a research note. The analyst is a buyer into the data and keeps an Overweight rating on BioMarin shares with a $120 price target.
10/21/19
CANT
10/21/19
NO CHANGE
Target $129
CANT
Overweight
Cantor sees successful vosoritide Phase 3 trial for BioMarin by year end
Cantor Fitzgerald analyst Eliana Merle reiterates an Overweight rating on BioMarin with a $129 price target saying she has "high conviction" in a successful vosoritide Phase 3 trial by the end of 2019. This will be a key catalyst of focus for the shares, Merle tells investors in a research note. The analyst hosted Dr. Jonathan Day, the clinical lead for BioMarin's vosoritide program for achondroplasia, for a conference call on Friday and thinks Day sounded highly confident in Phase 3 success for vosoritide, "especially given powering assumptions." Merle thinks a successful Phase 3 will support further near-term revenue growth and profitability for BioMarin. On a successful Phase 3, the shares could trade up 10%-20% versus downside risk of ~20%, contends the analyst.
10/16/19
BOFA
10/16/19
INITIATION
Target $90
BOFA
Buy
BioMarin reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of BioMarin with a Buy rating and $90 price target, highlighting the base business's above average growth and a new product cycle on the way.
FBHS Fortune Brands
$58.73

0.22 (0.38%)

09/26/19
JPMS
09/26/19
UPGRADE
Target $172
JPMS
Overweight
JPMorgan upgrades Whirlpool to Overweight, boosts price target to $172
JPMorgan analyst Michael Rehaut upgraded Whirlpool (WHR) to Overweight from Neutral and raised his price target for the shares to $172 from $155. The analyst expects U.S. industry shipments to be more stable year-over-year through the end of 2019 and show "modest" growth in 2020. Further, he thinks point to steel prices will remain "at bay" and that Whirlpool's European operations will "finally" turn a small profit in the second half of 2019. In addition, Rehaut views the stock's valuation as inexpensive. The analyst this morning also downgraded Beacon Roofing Supply (BECN) to Underweight from Neutral. His top picks in the Building Products sector remain Stanley Black & Decker (SWK) and Fortune Brands (FBHS).
05/06/19
BOFA
05/06/19
UPGRADE
BOFA
Buy
Fortune Brands upgraded to Buy from Neutral at BofA/Merrill
07/02/19
LOOP
07/02/19
DOWNGRADE
LOOP
Hold
Fortune Brands downgraded to Hold from Buy at Loop Capital
Loop Capital analyst Laura Champine downgraded Fortune Brands Home & Security to Sell from Hold.
07/02/19
LOOP
07/02/19
DOWNGRADE
Target $50
LOOP
Sell
Fortune Brands downgraded to Sell at Loop Capital, $50 price target maintained
Loop Capital analyst Laura Champine downgraded Fortune Brands Home & Security to Sell from Hold with a $50 price target following the company's 20% bounce in the second quarter on top of a 25% move in the first quarter. In a research note to investors, Champine says that while lower mortgage rates may drive improving remodeling trends in the second half of the year, she feels this is more than sufficiently priced into the stock already. The analyst also says she is concerned that slower home price improvements may eventually create a headwind to remodeling activity that is not consistent with management's guidance.
SLM Sallie Mae
$9.10

0.04 (0.44%)

07/26/19
COMP
07/26/19
DOWNGRADE
COMP
Neutral
Sallie Mae downgraded to Neutral from Buy at Compass Point
Compass Point analyst Scott Valentin downgraded Sallie Mae to Neutral from Buy saying the shares will likely be range-bound given more limited catalysts and regulatory uncertainty.
06/03/19
WEDB
06/03/19
NO CHANGE
Target $13
WEDB
Outperform
Sallie Mae should be bought on weakness, says Wedbush
Wedbush analyst Henry Coffey notes that Sallie Mae stock's performance has been "dismal" over the last two years, despite significant growth in EPS and loan balances, and favorable trends in credit. College costs are rising, not falling, and his expectation is that Sallie Mae will continue to find paths of education-related lending that will allow it to support loan growth of 12%-15% a year and EPS growth of at least 12%. Coffey reiterates an Outperform rating and $13 price target on the shares and says he would be a buyer of the stock at current levels.
08/06/19
WEDB
08/06/19
NO CHANGE
WEDB
Replimune Group, Sallie Mae removed from Best Ideas List at Wedbush
Wedbush removed Replimune Group (REPL) and Sallie Mae (SLM) from its Best Ideas List due to its investment price discipline. The firm has an Outperform rating on both stocks.
08/22/19
SBSH
08/22/19
NO CHANGE
Target $11
SBSH
Buy
Sallie Mae added to US Focus List as a Buy at Citi
Citi analyst Arren Cyganovich added Sallie Mae to the firm's US Focus List as a Buy as he believes the shares are overly discounting credit and political risks. The analyst, who expects consensus EPS estimates to move up as investors adopt the company's new adjusted core EPS measure, keeps an $11 price target on Sallie Mae shares.
SAVE Spirit Airlines
$37.74

0.49 (1.32%)

09/23/19
SPHN
09/23/19
DOWNGRADE
Target $45
SPHN
Equal Weight
Spirit Airlines downgraded to Equal Weight from Overweight at Stephens
Stephens analyst Jack Atkins downgraded Spirit Airlines to Equal Weight from Overweight and lowered his price target for the shares to $45 from $55. With its heavy Southeast and Caribbean exposure, Spirit significantly lowered its Q3 guidance in early September due to Hurricane Dorian, Atkins tells investors in a research note. While the analyst continues to see long-term opportunities for the airline to drive higher non-ticket and ancillary revenues, he sees limited near-term catalysts, "particularly in the face of growing competition," noting that other airlines are successfully growing their discounted fare options. As a result, Atkins sees a more challenging backdrop for Spirit Airlines in 2020.
10/21/19
BUCK
10/21/19
NO CHANGE
Target $88
BUCK
Buy
Alaska Air price target raised to $88 from $78 at Buckingham
Buckingham analyst Daniel McKenzie raised his price target for Alaska Air (ALK) to $88 from $78 and lowered his price target for American Airlines (AAL) to $42 from $43. He maintained Buy ratings on both airline names ahead of Q3 earnings this week. In a research note to investors, McKenzie says the industry is set to deliver Q3 pre-tax profits of $5.8B, up 16.5% year-over-year, primarily on top line revenue growth. The analyst believes Alaska Air, American Airlines, Hawaiian Holdings (HA) and JetBlue (JBLU) are most likely to outperform on revenue and EPS execution, while he thinks Spirit Airlines (SAVE) is the most likely to disappoint.
09/23/19
09/23/19
DOWNGRADE

Fly Intel: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Alcoa (AA) downgraded to Neutral from Buy at Goldman Sachs. 2. Commercial Metals (CMC) was downgraded to Neutral from Buy at Goldman Sachs while Schnitzer Steel (SCHN) was downgraded to Sell from Neutral. 3. AK Steel (AKS) was downgraded to Underweight from Overweight at JPMorgan while Cleveland-Cliffs (CLF) and U.S. Steel (X) were downgraded to Neutral from Overweight. 4. Clorox (CLX) downgraded to Underweight from Equal Weight at Barclays. 5. Spirit Airlines (SAVE) downgraded to Equal Weight from Overweight at Stephens with analyst Jack Atkins saying with its heavy Southeast and Caribbean exposure, Spirit significantly lowered its Q3 guidance in early September due to Hurricane Dorian. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/13/19
MACQ
09/13/19
UPGRADE
Target $47
MACQ
Outperform
Spirit Airlines upgraded to Outperform from Neutral at Macquarie
Macquarie analyst Susan Donofrio upgraded Spirit Airlines to Outperform from Neutral and keeps a $47 price target on the shares.

TODAY'S FREE FLY STORIES

GLD

SPDR Gold Shares

$137.42

0.37 (0.27%)

19:00
11/12/19
11/12
19:00
11/12/19
19:00
Hot Stocks
SPDR Gold Shares holdings fall to 897.09MT from 901.19MT »

This is the lowest level…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PTE

PolarityTE

$2.89

-0.41 (-12.42%)

18:57
11/12/19
11/12
18:57
11/12/19
18:57
Recommendations
PolarityTE analyst commentary  »

PolarityTE price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

DK

Delek US

$38.45

-0.06 (-0.16%)

18:51
11/12/19
11/12
18:51
11/12/19
18:51
Hot Stocks
Delek US CFO sells 50K shares of common stock »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CDLX

Cardlytics

$39.85

0.17 (0.43%)

, TWOU

2U

$22.58

0.77 (3.53%)

18:44
11/12/19
11/12
18:44
11/12/19
18:44
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: …

CDLX

Cardlytics

$39.85

0.17 (0.43%)

TWOU

2U

$22.58

0.77 (3.53%)

OPNT

Opiant Pharmaceuticals

$15.95

0.18 (1.14%)

DDOG

Datadog

$34.40

0.89 (2.66%)

PTE

PolarityTE

$2.89

-0.41 (-12.42%)

ADPT

Adaptive Biotechnologies

$28.35

0.01 (0.04%)

ADT

ADT Inc.

$7.70

-0.02 (-0.26%)

BDSI

BioDelivery Sciences

$5.86

0.02 (0.34%)

AQMS

Aqua Metals

$1.45

-0.065 (-4.29%)

YY

YY

$65.12

-0.28 (-0.43%)

HUYA

Huya

$24.28

-1.05 (-4.15%)

RUN

Sunrun

$14.49

0.08 (0.56%)

VRAY

ViewRay

$2.48

-0.145 (-5.53%)

DZSI

Dasan Zhone

$8.34

0.5 (6.38%)

HIIQ

Health Insurance Innovations

$23.27

-1.71 (-6.85%)

CBPX

Continental Building

$35.76

3.73 (11.65%)

KNSL

Kinsale Capital Group

$88.98

1.78 (2.04%)

BOXL

Boxlight

$1.94

0.19 (10.86%)

SSTI

ShotSpotter

$20.36

(0.00%)

TVTY

Tivity Health

$18.56

0.145 (0.79%)

GEVO

Gevo

$2.57

0.065 (2.59%)

CSIQ

Canadian Solar

$17.51

0.65 (3.86%)

SDC

SmileDirectClub

$11.02

-0.83 (-7.00%)

SWKS

Skyworks

$101.59

1.22 (1.22%)

VREX

Varex Imaging

$32.68

0.1 (0.31%)

TLRY

Tilray

$21.57

-0.4 (-1.82%)

NXTC

NextCure

$37.41

-1.45 (-3.73%)

HALO

Halozyme

$16.77

0.18 (1.09%)

CYBR

CyberArk

$115.30

1.45 (1.27%)

I

Intelsat

$20.39

-2.845 (-12.24%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 19

    Nov

  • 19

    Nov

  • 20

    Nov

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

  • 03

    Dec

  • 04

    Dec

  • 04

    Dec

  • 05

    Dec

  • 07

    Dec

  • 09

    Dec

  • 09

    Dec

  • 10

    Dec

  • 10

    Dec

  • 17

    Dec

  • 15

    Nov

MU

Micron

$46.89

0.64 (1.38%)

18:44
11/12/19
11/12
18:44
11/12/19
18:44
Hot Stocks
Micron CEO: We are focused on new product introductions »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

WSFS

WSFS Financial

$44.57

0.12 (0.27%)

18:34
11/12/19
11/12
18:34
11/12/19
18:34
Hot Stocks
WSFS Financial names Rodger Levenson chairman of the board »

WSFS Financial…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

REAL

RealReal

$18.30

0.08 (0.44%)

18:34
11/12/19
11/12
18:34
11/12/19
18:34
Hot Stocks
RealReal CEO: Our brand is to keep fakes off the market »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 09

    Dec

  • 09

    Dec

USB

U.S. Bancorp

$58.49

-0.16 (-0.27%)

18:31
11/12/19
11/12
18:31
11/12/19
18:31
Hot Stocks
U.S. Bancorp receives Fed board of governors approval for capital distribution »

U.S. Bancorp announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 15

    Jan

IKTSY

Intertek

$0.00

(0.00%)

18:29
11/12/19
11/12
18:29
11/12/19
18:29
Upgrade
Intertek rating change  »

Intertek upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBPX

Continental Building

$35.76

3.73 (11.65%)

, CODYY

Saint-Gobain

$0.00

(0.00%)

18:27
11/12/19
11/12
18:27
11/12/19
18:27
Hot Stocks
Saint-Gobain to acquire Continental Building in roughly $1.4B deal »

Saint-Gobain (CODYY) and…

CBPX

Continental Building

$35.76

3.73 (11.65%)

CODYY

Saint-Gobain

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Nov

PYPL

PayPal

$102.07

-0.61 (-0.59%)

, FB

Facebook

$194.47

4.9 (2.58%)

18:22
11/12/19
11/12
18:22
11/12/19
18:22
Hot Stocks
PayPal CFO: We are a better company, stronger workforce with veterans »

In an interview on…

PYPL

PayPal

$102.07

-0.61 (-0.59%)

FB

Facebook

$194.47

4.9 (2.58%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Nov

  • 10

    Dec

EADSY

Airbus

$0.00

(0.00%)

, AFLYY

Air France-KLM

$0.00

(0.00%)

18:22
11/12/19
11/12
18:22
11/12/19
18:22
Periodicals
Airbus says could stretch A220 jet to carry more passengers, Reuters says »

Philippe Balducchi, head…

EADSY

Airbus

$0.00

(0.00%)

AFLYY

Air France-KLM

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CCNE

CNB Financial

$33.10

-0.23 (-0.69%)

18:21
11/12/19
11/12
18:21
11/12/19
18:21
Syndicate
CNB Financial offering up to $40M in 'at-the-market' common stock »

The shares will be…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.89

-4.08 (-1.11%)

, ALK

Alaska Air

$70.87

-1.015 (-1.41%)

18:18
11/12/19
11/12
18:18
11/12/19
18:18
Periodicals
U.S. carriers willing to take 737 jets before training clearance, Reuters says »

Certain U.S. airline…

BA

Boeing

$362.89

-4.08 (-1.11%)

ALK

Alaska Air

$70.87

-1.015 (-1.41%)

LUV

Southwest

$57.87

-0.4 (-0.69%)

DAL

Delta Air Lines

$57.23

(0.00%)

JBLU

JetBlue

$19.31

-0.44 (-2.23%)

UAL

United Airlines

$92.73

-0.77 (-0.82%)

SAVE

Spirit Airlines

$37.86

-0.9 (-2.32%)

AAL

American Airlines

$29.51

-1.08 (-3.53%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 14

    Nov

  • 14

    Nov

  • 12

    Dec

  • 23

    Jan

PBR

Petrobras

$15.65

-0.146 (-0.92%)

18:15
11/12/19
11/12
18:15
11/12/19
18:15
Hot Stocks
Petrobras discloses teaser for sale of assets in Uruguay »

Brazil's Petrobras…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

YY

YY

$65.12

-0.28 (-0.43%)

18:05
11/12/19
11/12
18:05
11/12/19
18:05
Hot Stocks
YY reports Q3 global average mobile MAUs 470.1M from 433.5M in Q2 »

Q3 Average mobile MAUs of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HUYA

Huya

$24.28

-1.05 (-4.15%)

18:04
11/12/19
11/12
18:04
11/12/19
18:04
Hot Stocks
Huya sees Q4 revenue up 55.5%-60.8% YoY »

Sees Q4 total net…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 09

    Dec

YY

YY

$65.12

-0.28 (-0.43%)

18:03
11/12/19
11/12
18:03
11/12/19
18:03
Earnings
Breaking Earnings news story on YY »

YY sees Q4 revenue up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

HUYA

Huya

$24.28

-1.05 (-4.15%)

18:03
11/12/19
11/12
18:03
11/12/19
18:03
Earnings
Huya reports Q3 EPS 7c, consensus 11c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 09

    Dec

YY

YY

$65.12

-0.28 (-0.43%)

18:01
11/12/19
11/12
18:01
11/12/19
18:01
Earnings
YY reports Q3 adjusted EPS 90c, consensus 80c »

Reports Q3 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

LAZ

Lazard

$38.51

-0.03 (-0.08%)

18:00
11/12/19
11/12
18:00
11/12/19
18:00
Hot Stocks
Lazard CAO sells 40,000 class A common shares »

In a regulatory filing,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BA

Boeing

$362.89

-4.08 (-1.11%)

17:53
11/12/19
11/12
17:53
11/12/19
17:53
Periodicals
Boeing moves pilot to new job following leaked messages, Reuters says »

One of two Boeing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

AVYA

Avaya

$12.53

0.08 (0.64%)

, RNG

RingCentral

$172.89

2.57 (1.51%)

17:45
11/12/19
11/12
17:45
11/12/19
17:45
Syndicate
Avaya files to sell 1.75M shares of RingCentral Class A common stock »

Avaya Holdings (AVYA)…

AVYA

Avaya

$12.53

0.08 (0.64%)

RNG

RingCentral

$172.89

2.57 (1.51%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 12

    Nov

  • 13

    Nov

  • 13

    Nov

  • 20

    Nov

  • 09

    Dec

17:45
11/12/19
11/12
17:45
11/12/19
17:45
General news
Breaking General news story  »

Minneapolis Federal…

NVTR

Nuvectra

$1.41

0.085 (6.44%)

17:37
11/12/19
11/12
17:37
11/12/19
17:37
Hot Stocks
Nuvectra to file voluntary petition for reorganization under Chapter 11 »

Nuvectra announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.